Article Text

Download PDFPDF
EP575 Patterns of relapse in endometrial cancer
  1. G McCormick,
  2. R Jyothirmayi,
  3. K Nathan,
  4. J Summers and
  5. C Mikropoulos
  1. Kent Oncology Centre, Maidstone, UK


Introduction/Background The treatment of patients with high risk endometrial cancer remains controversial, with PORTEC 3 reporting no significant overall survival benefit in patients receiving chemoradiotherapy compared with radiotherapy alone. In this study we reviewed the outcomes of patients who received adjuvant radiotherapy (± chemotherapy) to review patterns of relapse.

Methodology This retrospective study reviewed the clinical notes of 163 patients who were referred for adjuvant radiotherapy in Kent Oncology Centre, England between January 2012 - December 2016. Follow-up clinic appointments and scans were reviewed.

Results 163 patients received conformal adjuvant pelvic radiotherapy to a dose of 45Gy in 25 fractions. During the follow-up period 31 patients relapsed. The mean time to relapse was 14.7 months (range 1.3–37.6 months). Table 1 illustrates the staging, histology and treatments received by the patients who relapsed.

28 of the 31 patients with recurrent disease had widespread metastatic disease when diagnosed with recurrent disease, and 3 patients had local recurrence only. The sites of local recurrence, details of the histology and treatment received and site of recurrence in relation to the PTV and isodose level are illustrated in table 2.

Conclusion The majority of patients with recurrent endometrial cancer relapsed with systemic disease. No patients with local recurrence only, relapsed within the radiotherapy CTV and all three patients with local relapse had endometriod histology. Although no overall survival benefit with systemic treatment was reported in Portec 3, our results are consistent with the Portec 3 findings that endometrial disease recurrence is usually a systemic event and local recurrence is rare. Our focus for improving outcomes from endometrial cancer should be on systemic therapies.

Disclosure Nothing to disclose.

Abstract EP575 Table 1

Abstract EP575 Table 2

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.